

Prescriber Guide

Important safety information concerning Orphacol® (cholic acid)

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Orphacol® is indicated for the treatment of inborn errors in primary bile acid synthesis due to 3 β -hydroxy- Δ^5 -C₂₇-steroid oxidoreductase deficiency or Δ^4 -3-oxosteroid-5 β -reductase deficiency.

This prescriber guide for gastroenterologists/hepatologists aims to:

- Provide correct diagnosis and therapeutic managements of these two deficiencies;
- Inform on expected and potential risks associated with the treatment, especially prescription of a suprathreshold dose and gallstones.

Table of contents

1. What are 3 β -hydroxy- Δ^5 -C ₂₇ -steroid oxidoreductase deficiency and Δ^4 -3-oxosteroid-5 β -reductase deficiency?	3
2. How are 3 β -hydroxy- Δ^5 -C ₂₇ -steroid oxidoreductase deficiency and Δ^4 -3-oxosteroid-5 β -reductase deficiency diagnosed?	3
3. Dose considerations to avoid supratherapeutic dose.	4
4. How is Orphacol [®] administered?	6
5. What are expected and potential risks associated with the treatment? What are signs of overdose? What should be done if gallstones are found?	6
6. Contacts	7
7. Bibliography	8
Diagnostic flowchart.....	11

1. What are 3 β -hydroxy- Δ^5 -C₂₇-steroid oxidoreductase deficiency and Δ^4 -3-oxosteroid-5 β -reductase deficiency?

Two main types of primary bile acid synthesis defects have been identified including 3 β -hydroxy- Δ^5 -C₂₇-steroid oxidoreductase [3 β -HSD] (microsomal enzyme) deficiency and Δ^4 -3-oxosteroid-5 β -reductase [Δ^4 -3-oxoR] (cytosolic enzyme) deficiency. These two enzymes are involved early in the bile acid synthetic pathway and the consequences of abnormalities in these enzymes are absence of primary bile acid synthesis and accumulation of abnormal bile acid metabolites that are cholestatic and toxic for the liver. This results in cholestasis followed by irreversible progressive liver failure in the absence of treatment.

We are collecting treatment information in a central database called Orphabase. You are invited to participate to this collaborative effort by entering treatment data of patients with 3 β -hydroxy- Δ^5 -C₂₇-steroid dehydrogenase/isomerase or Δ^4 -3-oxosteroid-5 β -reductase deficiency in your care into this database. You would then be able to access and use the data that you enter at any time. If you are interested in participating in this database or would like to get more information, please contact CTRS. Moreover, any suspected adverse reactions should be reported to CTRS or the national competent authorities (see safety information in section 5 and the list of contacts in section 6).

2. How are 3 β -hydroxy- Δ^5 -C₂₇-steroid oxidoreductase deficiency and Δ^4 -3-oxosteroid-5 β -reductase deficiency diagnosed?

The following signs are suggestive of the diagnosis of 3 β -HSD or Δ^4 -3-oxoR deficiency:

- Cholestasis and/or hepatocellular insufficiency during the first months of life or in childhood,
- And/or malabsorption syndrome (steatorrhoea, clinical signs associated with fat-soluble vitamin deficiencies),
- And/or cirrhosis or hepatomegaly.

With unexplained elevation of serum transaminases and conjugated bilirubin in combination with:

- An absence of pruritus.
- Normal serum gamma-glutamyl transferase (GGT) activity,
- Normal or very low total serum bile acids.

Hepatic histological signs include:

- Canalicular cholestasis, without bile duct proliferation and sometimes with signs of giant-cell hepatitis.
- Portal and lobular fibrosis with features of septal fibrosis or cirrhosis depending on the stage.

Confirmation of diagnosis

Initial confirmation of the diagnosis is based on urinary and serum bile acid analysis by gas chromatography linked to mass spectrometry (GC-MS) and/or electrospray ionization tandem spectrometry (ESI-MS/MS)(4) or equivalent technology coupled to mass spectrometry. This analysis demonstrates a typical profile for each deficiency, confirming the specific diagnosis. Analysis of the *HSD3B7* or *AKR1D1 (SRD5B1)* genes also enables a subsequent confirmation of the diagnosis.

Please refer to the list of qualified laboratories who perform the required analyses in section 6.

You may also contact CTRS directly if you need assistance with bile acid analysis.

A diagnostic Flow Chart is shown on the latest page of this prescriber guide (page 11) .

3. Dose considerations to avoid suprathreshold dose.

Treatment with Orphacol® must be initiated and monitored by an experienced gastroenterologist/hepatologist or a paediatric gastroenterologist/hepatologist in the case of paediatric patients. Patients should be monitored as follows: 3-monthly during the first year, 6-monthly during the subsequent three years and annually thereafter to avoid administration of a suprathreshold dose.

The daily dose to treat 3β -hydroxy- Δ^5 -C₂₇-steroid oxidoreductase and Δ^4 -3-oxosteroid-5 β -reductase deficiencies ranges from 5 to 15 mg/kg in infants, children, adolescents and adults. In all age groups, the minimum dose is 50 mg and the dose is adjusted in 50 mg steps. In adults, the daily dose should not exceed 500 mg.

The daily dose may be divided if it consists of more than one capsule.

The following table gives indication on the estimated number of capsules to be administered for infants and young children.

Weight (kg)	Dose in mg/kg*										
	5	6	7	8	9	10	11	12	13	14	15
3	0	0	0	0	1	1	1	1	1	1	1
4	0	0	1	1	1	1	1	1	1	1	1
5	1	1	1	1	1	1	1	1	1	1	2
6	1	1	1	1	1	1	1	1	2	2	2
7	1	1	1	1	1	1	2	2	2	2	2
8	1	1	1	1	1	2	2	2	2	2	2
9	1	1	1	1	2	2	2	2	2	3	3
10	1	1	1	2	2	2	2	2	3	3	3
11	1	1	2	2	2	2	2	3	3	3	3
12	1	1	2	2	2	2	3	3	3	3	4
13	1	2	2	2	2	3	3	3	3	4	4
14	1	2	2	2	3	3	3	3	4	4	4
15	2	2	2	2	3	3	3	4	4	4	1 x 250 mg
16	2	2	2	3	3	3	4	4	4	4	1 x 250 mg
17	2	2	2	3	3	3	4	4	4	1 x 250 mg	1 x 250 mg
18	2	2	3	3	3	4	4	4	1 x 250 mg	1 x 250 mg	1 x 250 mg
19	2	2	3	3	3	4	4	1 x 250 mg	1 x 250 mg	1 x 250 mg	1 x 50 mg + 1 x 250 mg
20	2	2	3	3	4	4	4	1 x 250 mg	1 x 250 mg	1 x 50 mg + 1 x 250 mg	1 x 50 mg + 1 x 250 mg

* The individual numbers in this table refer to 50 mg capsule

Monitoring of patients

During the initiation of Orphacol® therapy and dose adjustment, serum and/or urine bile acid levels should be monitored intensively (at least every three months during the first year of treatment, every six months during the second year) using gas chromatography-mass spectrometry (GC-MS) or equivalent technology coupled to mass spectrometry. Patients that have previously been treated with other bile acids or other cholic acid preparations should be closely monitored in the same manner. Please refer to the list of qualified laboratories in section 6. You may also contact CTRS directly if you need assistance with bile acid analysis.

The concentrations of the abnormal bile acid metabolites synthesised in 3β-hydroxy-Δ⁵-C₂₇-steroid oxidoreductase deficiency (3β, 7α-dihydroxy- and 3β, 7α, 12α-trihydroxy-5-cholenoic acids) or in Δ⁴-3-oxosteroid-5β-reductase deficiency (3-oxo-7α-hydroxy- and 3-oxo-7α, 12α-dihydroxy-4-cholenoic acids) should be determined. At each investigation, the need for dose adjustment should be considered. **The lowest dose of Orphacol® that effectively reduces the bile acid metabolites to as close to zero as possible should be chosen.**

Liver parameters should also be monitored, preferentially more frequently than serum and/or urine bile acid levels.

Concurrent elevation of serum gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT) and/or serum bile acids above normal levels **may indicate overdose**. Transient elevations of transaminases at the initiation of cholic acid treatment have been observed and do not indicate the need for a dose reduction if GGT is not elevated and if serum bile acid levels are falling or in the normal range.

Particular attention must be paid to the observation that infants need higher cholic acid doses on a per kilogram basis than adolescents and adults to achieve metabolic control. Maintaining the initial per kilogram dosage may hence lead to overdose. The lowest effective dose should be actively titrated.

After the initiation period, serum and/or urine bile acids (using mass spectrometry technology) and liver parameters should be determined annually, at a minimum, and the dose adjusted accordingly. Additional or more frequent investigations should be undertaken to monitor therapy during periods of fast growth, concomitant disease and pregnancy.

Treatment with Orphacol® should be stopped if in case of abnormal hepatocellular function, as measured by prothrombin time, does not improve within 3 months of the initiation of Orphacol® treatment. A concomitant decrease of urine total bile acids should be observed. Treatment should be stopped earlier if there are clear indicators of terminal hepatic disease.

In case of persistent lack of therapeutic response to Orphacol® monotherapy, another treatment option should be considered.

4. How is Orphacol® administered?

Orphacol® capsules must be taken with food at approximately the same time each day, in the morning and/or evening. Capsules must be swallowed whole with water, without chewing.

For infants and children who cannot swallow capsules, the capsules may be opened and the content added to infant formula, or infant-adapted apple/orange or apple/apricot juice. Other food such as fruit compote or yoghurt may be suitable for administration, but no data on the compatibility or palatability are available.

5. What are expected and potential risks associated with the treatment?

What are signs of overdose?

What should be done if gallstones are found?

Overdose

Episodes of **symptomatic overdose** have been reported, including accidental overdose. Clinical features were limited to **pruritus and diarrhoea**. In laboratory investigations, **serum transaminase and bile acid levels were increased**. Reduction of the dose led to resolution of the clinical signs and correction of abnormal laboratory parameters. In the case of an accidental overdose, treatment should be continued at the recommended dose after normalisation of clinical signs and/or biological abnormalities.

Particular attention must be paid to the observation that infants need higher cholic acid doses on a per kilogram basis than adolescents and adults to achieve metabolic control. Maintaining the

initial per kilogram dosage may hence lead to overdose. The lowest effective dose should be actively titrated. Younger and lighter patients appear to require and tolerate higher doses per body weight than older children. This is probably related to the observation reported by Heubi (Heubi et al. 1982) that infants and children have about 40 % larger CA pool size than adults.

Undesirable effects

- **Gallstones** have been reported after long-term therapy. **Any occurrence of gallstones should be reported as an adverse reaction** to national competent authority or to CTRS (see the list of contacts in section 6).
- The **development of pruritus and/or diarrhoea as well as increased serum transaminase and bile acid levels** has been observed during treatment with Orphacol. These reactions abated after dose reduction and are **suggestive of overdose**. Patients presenting with pruritus and/or persistent diarrhoea **should be investigated** for a potential overdose by a serum and/or urine bile acid assay.

Please refer to the Summary of Product Characteristics for a full list of undesirable effects potentially associated with Orphacol treatment (available on EMA website: <https://www.ema.europa.eu/en/medicines/human/EPAR/orphacol>).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Please report any suspected adverse reactions via HPRA Pharmacovigilance (Website: www.hpra.ie).

For the complete information regarding safety of Orphacol, please refer to the Summary of Product Characteristics available on EMA website listed above.

6. Contacts

Details of the national competent authorities to communicate adverse reactions

Ireland

HPRA Pharmacovigilance

Website: www.hpra.ie

Details of the Marketing Authorisation Holder to communicate adverse reactions

ctrs@ctrs.fr

Tel: +44 (0)3 301 002 375

Analytical Laboratories

PARIS

Laboratoire de Biologie
c/o Chef du Service de biologie/Head of the laboratory
Groupe hospitalier Paris Saint-Joseph
185, rue Raymond Losserand
75014 Paris
FRANCE
Tel: +33 1 44 12 34 54

NB: this list will be continuously updated as CTRS identifies more analytical laboratories in Europe with the required capacity and expertise.

Laboratoires CTRS

63, rue de l'Est
F-92100 Boulogne Billancourt
Tel: +44 (0)3 301 002 375
Email: ctrs@ctrs.fr

7. Bibliography

1. Clayton PT, Leonard JV, Lawson AM, Setchell KD, Andersson S, Egestad B, et al. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. *J Clin Invest.* 1987 Apr;79(4):1031–8.
2. Setchell KD, Suchy FJ, Welsh MB, Zimmer-Nechemias L, Heubi J, Balistreri WF. Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis. *J Clin Invest.* 1988 Dec;82(6):2148–57.
3. Jacquemin E, Setchell KD, O'Connell NC, Estrada A, Maggiore G, Schmitz J, et al. A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. *J Pediatr.* 1994 Sep;125(3):379–364.
4. Setchell KDR, O'Connell NC. Disorders of bile acid synthesis and metabolism: a metabolic basis for liver disease. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. *Liver disease in children.* Third edition. Cambridge: Cambridge University Press; 2007. p. 736–766.

5. Gonzales E, Gerhardt MF, Fabre M, Setchell KDR, Davit-Spraul A, Vincent I, et al. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. *Gastroenterology*. 2009;137:1310–20.
6. Subramaniam P, Clayton PT, Portmann BC, Mieli-Vergani G, Hadzic N. Variable clinical spectrum of the most common inborn error of bile acid metabolism--3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency. *J Pediatr Gastroenterol Nutr*. 2010 Jan;50(1):61–6.
7. Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. *Semin Liver Dis*. 2007 Aug;27(3):282–94.
8. Sjövall J, Lawson AM, Setchell KD. Mass spectrometry of bile acids. *Methods Enzymol*. 1985;111:63–113.
9. Setchell KD, Matsui A. Serum bile acid analysis. *Clin Chim Acta Int J Clin Chem*. 1983 Jan 7;127(1):1–17.
10. Cheng JB, Jacquemin E, Gerhardt M, Nazer H, Cresteil D, Heubi JE, et al. Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. *J Clin Endocrinol Metab*. 2003 Apr;88(4):1833–41.
11. Schwarz M, Wright AC, Davis DL, Nazer H, Bjorkhem I, Russell DW. The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. *J Clin Invest*. 2000 Nov;106(9):1175–84.
12. Gonzales E, Cresteil D, Baussan C, Dabadie A, Gerhardt MF, Jacquemin E. SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect. *J Hepatol*. 2004 Apr;40(4):716–8.
13. Lemonde HA, Custard EJ, Bouquet J, Duran M, Overmars H, Scambler PJ, et al. Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. *Gut*. 2003 Oct;52(10):1494–9.
14. Gonzales E, Jacquemin E. Cholestases néonatales. *Pédiatrie*. 2006;4-060-A-15:1–8.
15. Balow M, Margolis CZ, Schachtel B et al. Progressive familial intrahepatic cholestasis. *Pediatrics* 1973; 51: 996-1007.
16. Clayton RJ, Iber FL, Ruebner BH et al. Byler disease: fatal familial intrahepatic cholestasis in an Amish kindred. *Am J Dis Child* 1969; 117: 112-124
17. Linarelli LG, Williams CN, Phillips MJ. Byler's disease: fatal intrahepatic cholestasis. *J Pediatr* 1972; 81: 484-492.
18. Riely CA. Familial intrahepatic cholestasis syndromes. In: Suchy FJ, eds. *Mosby Year Book* 1994: 443-459.
19. Whittington PF, Freese OK, Alonso EM et al. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. *J. Pediatr. Gastroenterol Nutr*. 1994; 18: 134-141.
20. Williams CN, Kaye R, Baker L et al. Progressive familial cholestatic cirrhosis and bile acid metabolism. *J Pediatr* 1972; 61: 493-500.

21. Charbonneau A, Luu-the V. Assignment of steroid 5 β -reductase (SRD5B1) and its pseudogene (SRD5BP1) to chromosome bands 7q32-q33 and 1q23-q25, respectively, by in situ hybridization. *Cytogenet Cell Genet* 1999; 64: 105-106.
22. Kondo KH, Kai MH, Setoguchi VS et al. Cloning and expression of cDNA of human Δ^4 -3 oxosteroid 5 β -reductase and substrate specificity of the expressed enzyme. *Eur J Biochem* 1994; 219: 357-363.
23. Kobayashi M, Koike M, Sakiyama M et al. 3beta-hydroxy-delta5-C₂₇-steroid dehydrogenase/isomerase deficiency in a 23-year-old woman. *Pediatr Int* 2000; 42: 685-688.
24. Fischler B, Bodin K, Sterjnman H et al. Cholestatic liver disease in adults may be due to an inherited defect in bile acid biosynthesis. *J Intern Med* 2007; 262: 254-262.
25. Daugherty CC, Setchell KDR, Heubi JE et al. Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta4-3-oxosteroid 5beta-reductase deficiency). *Hepatology*. 1993; 16: 1096-1101.
26. Jacquemin E, Gerhardt M, Cresteil O et al. Long term effects of bile acid therapy in children with defects of primary bile acid synthesis. In *Biology of bile acids in health and disease*; In Paumgartner G, Keppler D, Leuschner U, Stiehl A, GP van Berge Henegouwen editors. Kluwer Academic Publishers, Dordrecht 2001, 276-264.
27. Gonzales E, Matarazzo L, Franchi-Abella S, et al. Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood. *Orphanet J Rare Dis*. 2018;13(1):190.
28. Bentué-Ferrer D, Verdier M, Tribut O. Suivi thérapeutique pharmacologique de la primidone et du phénobarbital [Therapeutic drug monitoring of primidone and phenobarbital]. *Therapie*. 2012;67(4):381-90.
29. Lenkathula N, Cascella M. Primidone. [Updated 2021 Jul 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562297/>
30. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. *Epileptic Disord*. 2014;16(4):409-31.
31. Eusufzai S, Ericsson S, Cederlund T, Einarsson K, Angelin B. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. *Gut*. 1991;32(9):1044-8.
32. Ravindranath A, Sen Sarma M, Yachha S. Bile acid synthetic defects: Simplified approach in a nutshell. *Hepatobiliary Pancreat Dis Int*. 2020;19(1):80-4.
33. Stiehl A. Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment. *Ital J Gastroenterol*. 1995;27(4):193-5.

Diagnostic flowchart

